Nicolas Demogeot

Randomized phase III trial with a factorial design assessing the efficacy and safety of darolutamide and stereotactic dose-escalated radiotherapy in patients with high-risk localized prostate cancer: the PEACE 7 (GETUG-AFU 45) study protocol

Approximately 15% of patients with localized prostate cancer harbor high risk features. Nowadays, the standard of care for such patients is the combination of androgen deprivation therapy (ADT) plus radiotherapy (hypofractionated or conventional dose escalated radiotherapy). A su...